论文部分内容阅读
目的研究曲尼司特联合缬沙坦治疗难治性Ig A肾病效果及安全性。方法 127例难治性Ig A肾病患者,按治疗用药不同分为实验组(67例)和对照组(60例)。对照组采用传统治疗方法单用缬沙坦,实验组在对照组基础上加用曲尼司特,对比两组患者24 h尿蛋白定量、患者对治疗效果满意评价、血肌酐含量、平均动脉血压、不良反应发生率等情况。结果运用曲尼司特联合缬沙坦治疗难治性Ig A肾病的实验组患者的24 h尿蛋白定量、血肌酐含量、平均动脉血压等情况明显好于只单纯应用缬沙坦的对照组患者,差异有统计学意义(P<0.05)。实验组难治性Ig A肾病患者的治疗效果满意评价为(89.45±3.23)明显好于对照组,差异有统计学意义(P<0.05)。实验组不良反应发生率为1.49%(1/67),对照组为1.67%(1/60),两组患者比较差异无统计学意义(P>0.05)。结论曲尼司特联合缬沙坦能够显著提升难治性Ig A肾病患者的治疗效果,且多种药物的混用没有提高不良反应率,保证了难治性Ig A肾病患者的满意度,值得大力推广使用。
Objective To study the efficacy and safety of tranilast combined with valsartan in the treatment of refractory IgA nephropathy. Methods A total of 127 patients with refractory IgA nephropathy were randomly divided into experimental group (67 cases) and control group (60 cases). The control group was treated with valsartan alone. The experimental group was given tranilast on the basis of the control group. The 24-hour urinary protein was compared between the two groups. The patients’ satisfaction with the therapeutic effect, serum creatinine, mean arterial pressure , The incidence of adverse reactions and so on. Results In the experimental group treated with tranilast combined with valsartan for refractory IgA nephropathy, 24-hour urinary protein, serum creatinine, and mean arterial blood pressure were significantly better in the experimental group than those in the valsartan-only control group , The difference was statistically significant (P <0.05). The treatment group with refractory IgA nephropathy in the experimental group was significantly better than the control group (89.45 ± 3.23), with significant difference (P <0.05). The incidence of adverse reactions in the experimental group was 1.49% (1/67) in the control group and 1.67% (1/60) in the control group, with no significant difference between the two groups (P> 0.05). Conclusion Tranilast combined with valsartan can significantly improve the treatment of patients with refractory IgA nephropathy, and mixed with a variety of drugs did not increase the adverse reaction rate, to ensure the satisfaction of patients with refractory IgA nephropathy, it is worth vigorously Promote use.